-  INCLUSION CRITERIA:

          -  Patients must have histologically proven metastatic clear cell renal carcinoma with
             greater than or equal to 5% expression of PD-L1 on the tumor cells confirmed by IHC in
             the NCI Lab of Pathology.Archival tumor sample may be used but if archival tissue is
             not available or is not adequate, tissue biopsy will be required.

          -  Patients must have failed or relapsed and have progressive disease after at least 2
             prior therapies that include multityrosine kinase inhibitor (mTKI) like axitinib or
             sunitinib and an anti-PD1 or PD-L1 (ICI) therapy like nivolumab which could have been
             administered in combination with an anti-CTLA4 agent like ipilimumab. Patients who
             received an ICI in combination with a mTKI would be eligible for the trial if they
             received another appropriate treatment. Adjuvant or neoadjuvant with either type of
             agent would not fulfill this requirement only treatment for metastatic disease will be
             considered to satisfy this criterion.

          -  Disease must be measurable with at least one measurable lesion by Recist v1.1 criteria
             that is different from the lesion biopsied.

          -  Age >=18 years

        NOTE: Because no dosing or adverse event data are currently available on the use of rhIL-15
        in combination with avelumab in patients <18 years of age, children are excluded from this
        study, but may be eligible for future pediatric trials

          -  ECOG performance status <= 1 (Karnofsky >=80%)

          -  Adequate organ and marrow function as defined below:

               -  absolute neutrophil count greater than or equal to 1,500/mcL

               -  absolute lymphocyte count greater than or equal to 500/mcL

               -  Hemoglobin greater than or equal to 10 g/dL

               -  Platelets greater than or equal to 100,000/mcL

               -  total bilirubin less than or equal to 1.5 X institutional upper limit of normal
                  (ULN)

               -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional ULN

               -  Serum creatinine less than or equal to 1.5 X institutional ULN

        OR

          -  Creatinine clearance greater than or equal to 50 mL/min/1.73 m^2 for patients with
             creatinine levels >1.5 institutional ULN

          -  Negative serum or urine pregnancy test at screening for women of childbearing
             potential (WOCBP).

        NOTE: WOCBP is defined as any female who has experienced menarche and who has not undergone
        successful surgical sterilization or who is not postmenopausal. WOCBP must have a negative
        pregnancy test (HCG blood or urine) during screening.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation, and 1 month after completion of rhIL-15 and
             avelumab administration. Should a woman become pregnant or suspect she is pregnant
             while she or her partner is participating in this study, she should inform her
             treating physician immediately.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C).

          -  Persisting toxicity related to prior therapy of grade > 1, with the exception of the
             following: alopecia, sensory neuropathy grade <= 2, or other grade <= 2 not
             constituting a safety risk based on investigator's judgement.

          -  Patients who are receiving any other investigational agents

          -  Current use of immunosuppressive medication, EXCEPT for the following:

               -  Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,
                  intra-articular injection)

               -  Systemic corticosteroids at physiologic doses <= 10 mg/day of prednisone or
                  equivalent; or,

               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                  premedication).

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

          -  Patients with previous malignant disease other than the target malignancy within the
             last 5 years with the exception of basal or squamous cell carcinoma of the skin or
             cervical carcinoma in situ.

          -  Patients with history of any organ transplantation

          -  Vaccination within 4 weeks of the first dose of avelumab. Vaccination with a live
             vaccine while on trial is prohibited.

        NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
        are allowed; however intranasal influenza vaccines (e.g., Flu-Mist ) are live attenuated
        vaccines, and are not allowed.

          -  Patients with history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to rhIL-15 or avelumab.

          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
             or active infection requiring systemic therapy, or psychiatric illness/social
             situations that would limit compliance with study requirements.

          -  Inability or refusal to practice effective contraception during therapy or the
             presence of pregnancy or active breastfeeding. Based on its mechanism of action,
             avelumab can cause fetal harm when administered to a pregnant woman. Animal studies
             have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk
             of immune-mediated rejection of the developing fetus resulting in fetal death. These
             potential risks may also apply to other agents used in this study.

          -  Patients with active bacterial infections, documented HIV infection or positive
             screening serology, PCR evidence for active or chronic hepatitis B or hepatitis C, or
             positive screening HBV/HCV serology without documentation of successful curative
             treatment

          -  Patients with active or history of any autoimmune disease, including asthma requiring
             chronic inhaled or oral corticosteroids, or with history of asthma requiring
             mechanical ventilation; patients with a history of mild asthma that are on or can be
             switched to noncorticosteroid bronchodilator regimens are eligible

          -  Cardiovascular disease: Clinically significant (i.e., active) cardiovascular disease:
             cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial
             infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure
             (greater than or equal to New York Heart Association Classification Class II), or
             serious cardiac arrhythmia requiring medication

          -  Other severe acute or chronic medical conditions including immune colitis,
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric
             conditions including recent (within the past year) or active suicidal ideation or
             behavior; or laboratory abnormalities that may increase the risk associated with study
             participation or study treatment administration or may interfere with the
             interpretation of study results and, in the judgment of the investigator, would make
             the patient inappropriate for entry into this study.